Tony Butler
Stock Analyst at Rodman & Renshaw
(1.35)
# 2,539
Out of 4,479 analysts
103
Total ratings
33.33%
Success rate
-11.95%
Average return
Main Sectors:
Top Industries:
32 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MURA Mural Oncology | Initiates: Buy | $15 | $3.05 | +391.80% | 1 | Jun 28, 2024 | |
| LPTX Leap Therapeutics | Initiates: Buy | $8 | $1.69 | +373.37% | 1 | Jun 28, 2024 | |
| IPSC Century Therapeutics | Reiterates: Buy | $16 | $2.21 | +623.98% | 5 | Aug 10, 2023 | |
| ADAP Adaptimmune Therapeutics | Reiterates: Buy | $10 | $1.05 | +852.38% | 8 | Aug 10, 2023 | |
| FATE Fate Therapeutics | Reiterates: Buy | $10 | $3.22 | +210.56% | 4 | Aug 9, 2023 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Buy | $75 | $53.12 | +41.20% | 7 | Aug 8, 2023 | |
| MRUS Merus | Reiterates: Buy | $35 | $53.09 | -34.07% | 7 | Aug 8, 2023 | |
| GTBP GT Biopharma | Reiterates: Hold | $60 | $2.88 | +1,983.33% | 5 | Aug 7, 2023 | |
| CGEN Compugen | Reiterates: Buy | $13 | $1.69 | +669.23% | 6 | Aug 7, 2023 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $50 | $19.81 | +152.40% | 5 | Aug 3, 2023 | |
| ALLO Allogene Therapeutics | Reiterates: Buy | $15 | $2.16 | +594.44% | 7 | Aug 3, 2023 | |
| GTHX G1 Therapeutics | Reiterates: Buy | $19 | $2.45 | +675.51% | 4 | Aug 2, 2023 | |
| BCAB BioAtla | Reiterates: Buy | $25 | $1.32 | +1,793.94% | 6 | Aug 2, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $43 | $4.43 | +870.65% | 3 | Aug 1, 2023 | |
| PYXS Pyxis Oncology | Initiates: Buy | $15 | $2.94 | +410.20% | 1 | Jul 31, 2023 | |
| VIRX Viracta Therapeutics | Initiates: Buy | $10 | $0.49 | +1,940.82% | 1 | Jul 31, 2023 | |
| CVM CEL-SCI | Reiterates: Buy | $10 | $1.09 | +817.43% | 3 | Jul 12, 2023 | |
| CALC CalciMedica | Reiterates: Buy | $17 | $4.01 | +323.94% | 2 | Jul 7, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $14.28 | +1,062.46% | 4 | Jul 3, 2023 | |
| REPL Replimune Group | Reiterates: Buy | $60 | $8.37 | +616.85% | 4 | Jun 7, 2023 | |
| INAB IN8bio | Reiterates: Buy | $8 | $0.81 | +889.73% | 4 | Jun 5, 2023 | |
| VNRX VolitionRx | Assumes: Buy | $6 | $0.63 | +852.38% | 1 | Jun 1, 2023 | |
| HCWB HCW Biologics | Assumes: Buy | $9 | $0.62 | +1,351.61% | 1 | Jun 1, 2023 | |
| OCEA Ocean Biomedical | Assumes: Buy | $17 | $1.10 | +1,445.45% | 1 | May 25, 2023 | |
| ATRA Atara Biotherapeutics | Initiates: Buy | $25 | $7.52 | +232.45% | 1 | Jan 5, 2023 | |
| GNTA Genenta Science | Initiates: Buy | $15 | $3.09 | +384.81% | 1 | Jan 5, 2023 | |
| MRKR Marker Therapeutics | Downgrades: Neutral | $30 → $10 | $5.24 | +90.84% | 1 | Feb 17, 2022 | |
| CMPX Compass Therapeutics | Initiates: Buy | n/a | $0.88 | - | 1 | Nov 19, 2021 | |
| TBIO Telesis Bio | Maintains: Neutral | $810 → $684 | $3.74 | +18,188.77% | 4 | Aug 4, 2021 | |
| NTLA Intellia Therapeutics | Maintains: Buy | n/a | $22.15 | - | 2 | Jun 28, 2021 | |
| PBLA Panbela Therapeutics | Initiates: Buy | $240,000 | $0.35 | +68,162,353.85% | 1 | Jun 28, 2021 | |
| NXTC NextCure | Initiates: Buy | n/a | $1.50 | - | 1 | Mar 2, 2020 |
Mural Oncology
Jun 28, 2024
Initiates: Buy
Price Target: $15
Current: $3.05
Upside: +391.80%
Leap Therapeutics
Jun 28, 2024
Initiates: Buy
Price Target: $8
Current: $1.69
Upside: +373.37%
Century Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $16
Current: $2.21
Upside: +623.98%
Adaptimmune Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $10
Current: $1.05
Upside: +852.38%
Fate Therapeutics
Aug 9, 2023
Reiterates: Buy
Price Target: $10
Current: $3.22
Upside: +210.56%
CRISPR Therapeutics AG
Aug 8, 2023
Reiterates: Buy
Price Target: $75
Current: $53.12
Upside: +41.20%
Merus
Aug 8, 2023
Reiterates: Buy
Price Target: $35
Current: $53.09
Upside: -34.07%
GT Biopharma
Aug 7, 2023
Reiterates: Hold
Price Target: $60
Current: $2.88
Upside: +1,983.33%
Compugen
Aug 7, 2023
Reiterates: Buy
Price Target: $13
Current: $1.69
Upside: +669.23%
Bicycle Therapeutics
Aug 3, 2023
Reiterates: Buy
Price Target: $50
Current: $19.81
Upside: +152.40%
Allogene Therapeutics
Aug 3, 2023
Reiterates: Buy
Price Target: $15
Current: $2.16
Upside: +594.44%
G1 Therapeutics
Aug 2, 2023
Reiterates: Buy
Price Target: $19
Current: $2.45
Upside: +675.51%
BioAtla
Aug 2, 2023
Reiterates: Buy
Price Target: $25
Current: $1.32
Upside: +1,793.94%
Biomea Fusion
Aug 1, 2023
Reiterates: Buy
Price Target: $43
Current: $4.43
Upside: +870.65%
Pyxis Oncology
Jul 31, 2023
Initiates: Buy
Price Target: $15
Current: $2.94
Upside: +410.20%
Viracta Therapeutics
Jul 31, 2023
Initiates: Buy
Price Target: $10
Current: $0.49
Upside: +1,940.82%
CEL-SCI
Jul 12, 2023
Reiterates: Buy
Price Target: $10
Current: $1.09
Upside: +817.43%
CalciMedica
Jul 7, 2023
Reiterates: Buy
Price Target: $17
Current: $4.01
Upside: +323.94%
Agenus
Jul 3, 2023
Reiterates: Buy
Price Target: $166
Current: $14.28
Upside: +1,062.46%
Replimune Group
Jun 7, 2023
Reiterates: Buy
Price Target: $60
Current: $8.37
Upside: +616.85%
IN8bio
Jun 5, 2023
Reiterates: Buy
Price Target: $8
Current: $0.81
Upside: +889.73%
VolitionRx
Jun 1, 2023
Assumes: Buy
Price Target: $6
Current: $0.63
Upside: +852.38%
HCW Biologics
Jun 1, 2023
Assumes: Buy
Price Target: $9
Current: $0.62
Upside: +1,351.61%
Ocean Biomedical
May 25, 2023
Assumes: Buy
Price Target: $17
Current: $1.10
Upside: +1,445.45%
Atara Biotherapeutics
Jan 5, 2023
Initiates: Buy
Price Target: $25
Current: $7.52
Upside: +232.45%
Genenta Science
Jan 5, 2023
Initiates: Buy
Price Target: $15
Current: $3.09
Upside: +384.81%
Marker Therapeutics
Feb 17, 2022
Downgrades: Neutral
Price Target: $30 → $10
Current: $5.24
Upside: +90.84%
Compass Therapeutics
Nov 19, 2021
Initiates: Buy
Price Target: n/a
Current: $0.88
Upside: -
Telesis Bio
Aug 4, 2021
Maintains: Neutral
Price Target: $810 → $684
Current: $3.74
Upside: +18,188.77%
Intellia Therapeutics
Jun 28, 2021
Maintains: Buy
Price Target: n/a
Current: $22.15
Upside: -
Panbela Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $240,000
Current: $0.35
Upside: +68,162,353.85%
NextCure
Mar 2, 2020
Initiates: Buy
Price Target: n/a
Current: $1.50
Upside: -